VCNX's price/sales ratio is 74.5; that's higher than the P/S ratio of 96.45% of US stocks.
With a year-over-year growth in debt of 695.77%, Vaccinex Inc's debt growth rate surpasses 97.27% of about US stocks.
Vaccinex Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -79.19%, greater than the shareholder yield of only 4.45% of stocks in our set.
Stocks with similar financial metrics, market capitalization, and price volatility to Vaccinex Inc are ERYP, NVEC, CBIO, VNE, and PULM.
VCNX's SEC filings can be seen here. And to visit Vaccinex Inc's official web site, go to www.vaccinex.com.
Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is VX15 that is in Phase Ib/II clinical trials for the treatment of advanced solid tumors, including non-small cell lung cancer, osteosarcoma, and melanoma; and Phase II clinical trials for the treatment of Huntington’s disease. The company’s preclinical development products include VX5, a human antibody to CXCL13, a molecule that regulates the formation of immune tissues, for the treatment of MS and other autoimmune disorders; and VX25 is an investigational and bi-specific molecule for the therapeutic application of Natural Killer T cell stimulation for cancer immunotherapy. Vaccinex, Inc. was founded in 2001 and is based in Rochester, New York.
Biotech stock reversed course last week, dragged lower by the broader market weakness. The week's news flow was headlined by Johnson & Johnson (NYSE: JNJ ) kickstarting a Phase 3 trial of its coronavirus vaccine candidate. A few clinical readouts released during the week triggered strong moves. Vaccinex Inc (NASDAQ: VCNX ) and AC Immune SA (NASDAQ: ACIU ) were among the worst decliners of the week, with the former reacting to a failed mid-stage trial of lead drug in Huntington's disease, while the latter plunged after an out-licensed Alzheimer's drug flunked a mid-stage trial. Here are the key catalysts for the unfolding week. Conferences World Muscle Society, or WMS, 25: Virtual Congress: Sept. 28-Oct. 2 Annual Northeast Amyotrophic Lateral Sclerosis, or NEALS, meeting: Sept. 30- Oct. ...
NEW YORK, July 17, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BNED, VCNX, SEEL, PDSB, and SINT. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
Confused by the current financial landscape? You’re not alone. Unemployment is high, the Street is expecting a rough earnings season, yet in the face of this bad news, stocks have been charging forward. Add to the mix a rapidly rising rate of new COVID-19 infections, and you get a sense of the market’s clear disconnect. In times like these, traditional metrics alone might not tell the full story. You need other strategies to do the job.The activity of insiders can act as a more reliable trading signal. Who are these people in the know? They are the corporate officers and board members standing at the helm, entrusted with the task of steering their companies in the right direction. Given the nature of their positions, they have access to information before the general public, and thus, i...